Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial—PEARL

Martín et al. (Tue,) studied this question.

www.synapsesocial.com/papers/69dd489b99c691022d99bb6a — DOI: https://doi.org/10.1016/j.annonc.2020.12.013

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer· 2019 · 836 citations
2. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial· 2016 · 1,813 citations
3. The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology· 1993 · 15,845 citations
4. Multicenter Phase II Study of Capecitabine in Paclitaxel-Refractory Metastatic Breast Cancer· 1999 · 791 citations
5. An Overview of Statistical Planning to Address Subgroups in Confirmatory Clinical Trials· 2014 · 29 citations